key: cord-0268392-9jsx2z6e authors: Chemaitelly, H.; Tang, P.; Hasan, M. R.; AlMukdad, S.; YASSINE, H. M.; Benslimane, F.; Al Khatib, H. A.; Coyle, P.; Ayoub, H. H.; Al Kanaani, Z.; Al Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul Rahim, H. F.; Nasrallah, G.; Al Kuwari, M. G.; Al Romaihi, H. E.; Butt, A. A.; Al-Thani, M. H.; Al Khal, A.; Bertollini, R.; Abu-Raddad, L. J. title: Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar date: 2021-08-27 journal: nan DOI: 10.1101/2021.08.25.21262584 sha: 4db1e85e7c2b96aea39b1d5ee2f399ad3d281b05 doc_id: 268392 cord_uid: 9jsx2z6e BACKGROUND: Waning of vaccine protection against SARS-CoV-2 infection or COVID-19 disease is a concern. This study investigated persistence of BNT162b2 (Pfizer-BioNTech) vaccine effectiveness against infection and disease in Qatar, where the Beta and Delta variants have dominated incidence and PCR testing is done at a mass scale. METHODS: A matched test-negative, case-control study design was used to estimate vaccine effectiveness against SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19 disease, between January 1, 2021 to August 15, 2021. RESULTS: Estimated BNT162b2 effectiveness against any infection, asymptomatic or symptomatic, was negligible for the first two weeks after the first dose, increased to 36.5% (95% CI: 33.1-39.8) in the third week after the first dose, and reached its peak at 72.1% (95% CI: 70.9-73.2) in the first five weeks after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating [≥]15 weeks after the second dose, reaching diminished levels of protection by the 20th week. Effectiveness against symptomatic infection was higher than against asymptomatic infection, but still waned in the same fashion. Effectiveness against any severe, critical, or fatal disease increased rapidly to 67.7% (95% CI: 59.1-74.7) by the third week after the first dose, and reached 95.4% (95% CI: 93.4-96.9) in the first five weeks after the second dose, where it persisted at about this level for six months. CONCLUSIONS: BNT162b2-induced protection against infection appears to wane rapidly after its peak right after the second dose, but it persists at a robust level against hospitalization and death for at least six months following the second dose. misclassification of infection and differences in health care-seeking behavior between vaccinated and unvaccinated individuals. 14, 15 Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-one by sex, 10-year age group, nationality, reason for SARS-CoV-2 PCR testing, and calendar week of PCR test. Matching of cases and controls was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar. 11, [19] [20] [21] Only the first PCR-positive test during the study, January 1, 2021 to August 15, 2021, was included for each case, and only the first PCR-negative test during the study was included for each control. All PCR-negative tests for persons included as cases were excluded from analysis; that is no person was included as both a case and a control. These inclusion and exclusion criteria were implemented to control potential bias arising from repeated testing, such as a PCR-positive person undergoing a second PCR test a few days after infection diagnosis to test for clearance of infection. Modifications to these inclusion and exclusion criteria were investigated in sensitivity analyses as described below. Effectiveness was estimated against documented infection (defined as a PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms), as well as against any severe, 22 critical, 22 or fatal 23 COVID-19 disease. Classification of COVID-19 case severity (acute-care hospitalizations), 22 criticality (ICU hospitalizations), 22 and fatality 23 followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews. Each person who had a positive PCR test result and hospital admission was subject to an infection severity assessment every three days until discharge or death. Individuals who progressed to COVID-19 disease between the time of the PCR-positive test result and the end of the study were classified based on their worst outcome, starting with death, 23 followed by critical disease, 22 and then severe disease. 22 Details of the COVID-19 severity, criticality, and fatality classification are found in Supplementary Section 1. All records of PCR testing for those vaccinated and unvaccinated during the study were examined. All persons who received mixed vaccines, or who received a vaccine other than BNT162b2 were excluded. Every case that met the inclusion criteria and that could be matched to a control was included in the analysis. Both PCR-test outcomes and vaccination status were ascertained at the time of the PCR test. Institutional Review Boards with waiver of informed consent. Reporting of the study followed STROBE guidelines (Supplementary Table 1 ). Details of laboratory methods for real-time reverse-transcription PCR (RT-qPCR) testing are found in Supplementary Section 2. Methods for classification of infections by variant type using RT-qPCR variant screening 24 of random positive clinical samples 8, 10 are included in Supplementary Section 3. All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or at Sidra Medicine Laboratory, following standardized protocols. All records of PCR testing in Qatar during the study were examined in this study, but only samples of matched cases and controls were included in the analysis. Socio-demographic characteristics of study samples were described using frequency distributions and measures of central tendency. Differences in proportions across categorical variables between study groups All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint were evaluated using Chi-square tests. A two-sided p-value of <0.05 indicated a significant association. The odds ratio, comparing odds of vaccination among cases versus controls, and its associated 95% confidence interval (CI) were calculated using the exact method, or the Cornfield method, when no vaccinations were recorded among cases or controls. Confidence intervals were not adjusted for multiplicity. Interactions were not investigated. Vaccine effectiveness at different time points and its associated 95% CI were then calculated by applying the following equation: 14, 15 vaccinated among cases unvaccinated among controls Vaccine effectiveness 1 vaccinated among controls unvaccinated among cases To ensure that vaccine effectiveness estimates were not biased by epidemic phase, 14 ,25 the gradual roll-out of vaccination during the study, 14, 25 or other confounders, 26,27 a sensitivity analysis was conducted by adjusting for prior infection and matching factors in logistic regression, that is, by sex, age, nationality, reason for PCR testing, and calendar week of PCR test. Vaccine effectiveness was also estimated against symptomatic infection, defined as a PCRpositive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection, and against asymptomatic infection, defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection. In the latter case, PCR testing was done strictly as part of a survey, for pre-travel requirement, or at port of entry into the country. Vaccine effectiveness was further estimated in subgroup analyses stratifying cases and controls by age, variant type, or severe forms of COVID-19 disease. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Several additional sensitivity analyses were conducted by modifying the study inclusion and exclusion criteria or by incorporating an additional matching factor to investigate whether the effectiveness estimates could have been biased by an unknown factor. Descriptions of these sensitivity analyses can be found in Supplementary Section 4. To provide further validation of study results, effectiveness was further estimated by deriving adjusted odds ratios (AORs) from multivariable logistic regression analyses of associations with a PCR-positive test, using the full unmatched sample, that is, by applying a different method from that of the main analysis of matched test-negative, case-control study design. Statistical analyses were conducted in STATA/SE version 17.0. 28 Between December 21, 2020 and August 15, 2021, 927,321 individuals received at least one dose of BNT162b2, and 891,481 completed the two-dose regimen ( Figure 1A ). The median date at first dose was April 20, 2021, and the median date at second dose was May 9, 2021. The median time elapsed between the first and second doses was 21 days (interquartile range (IQR): 21-22 days), and 97.5% of individuals received their second dose ≤30 days after the first dose. Notably, during this period, 545,440 individuals received at least one dose of mRNA-1273, and 451,732 completed the two-dose regimen ( Figure 1A ). Supplementary Figure 1 presents a flowchart describing the population selection process for investigating and estimating BNT162b2 effectiveness against SARS-CoV-2 infection. Demographic characteristics and reasons for PCR testing of samples used to estimate vaccine All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint effectiveness are presented in Table 1. The median age of study subjects was 31-32 years, 70.6% were males, and subjects came from diverse national origins. Study samples were representative of the unique demographics of the population of Qatar. 11, 12 Only 25.9% of cases (PCR-confirmed infections) were diagnosed because of symptoms ( Table 1 ). The remaining cases were diagnosed because of PCR testing for other reasons, including contact tracing, random testing campaigns (surveys), individual requests, routine healthcare testing, pre-travel, and at port of entry. As of the end of the study, August 15, 2021, 8, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2 ). However, effectiveness declined gradually starting from 0-4 weeks after the second dose, and the decline accelerated ≥15 weeks after the second dose. Effectiveness was diminished ≥20 weeks after the second dose. A sensitivity analysis adjusting for prior infection, sex, age, nationality, reason for PCR testing, and calendar week of PCR test in logistic regression, confirmed main analysis results (Table 3) . BNT162b2 effectiveness was assessed for those <60 years of age and those ≥60, to investigate whether declining effectiveness over time could have been confounded by age. Results for both age groups were similar, in scale (but slightly lower for those ≥60 years of age), in pattern of declining effectiveness (Supplementary Table 2 ), and to those for all subjects of all age groups ( Table 2) . The above effectiveness measures largely reflect BNT162b2 effectiveness against Beta, 2,29 which was by far the dominant variant during most of these time periods. 2, 4, [8] [9] [10] However, with the steady increase in incidence of Delta during the summer of 2021, [8] [9] [10] 30 and the steady decline in Beta incidence during this time, 8 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 3 ) demonstrated a similar pattern to that seen against any SARS-CoV-2 infection ( Table 2 ). However, estimates for individual variants had wider 95% confidence intervals, because they were derived using smaller numbers of confirmed PCR-positive cases, that is, only those confirmed as Alpha, Beta, or Delta using RT-qPCR genotyping Estimated BNT162b2 effectiveness against each of symptomatic infection and asymptomatic infection demonstrated the same pattern of increasing effectiveness after the first dose, peak effectiveness in the first five weeks after the second dose, and a gradual decline in effectiveness in the following weeks that accelerated ≥20 weeks after the second dose for symptomatic infection, and ≥15 weeks after the second dose for asymptomatic infection (Table 4 ). However, effectiveness against symptomatic infection was consistently higher than that against All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Estimated BNT162b2 effectiveness against any severe, critical, or fatal disease due to any SARS-CoV-2 infection, was negligible for the first two weeks after the first dose. It increased rapidly to 67.7% (95% CI: 59.1-74.7) in the third week after the first dose, and reached a peak of 95.4% (95% CI: 93.4-96.9) in the first five weeks after the second dose (Table 2 and Figure 2 ). Unlike effectiveness against infection, there was no evident decline in this effectiveness over time. However, at ≥25 weeks after the second dose, there was a hint of a decline in effectiveness, but the case numbers were small. The sensitivity analysis adjusting for prior infection and the matching factors in logistic regression confirmed the main analysis results ( Table 3 ) also showed similar results. BNT162b2 effectiveness was also estimated against each of severe disease, critical disease, and fatal disease (Supplementary Table 4 ), as opposed to against a composite outcome of any severe, critical, or fatal disease ( Table 2 ). Estimated effectiveness against each of these individual disease outcomes was similar to that against the composite disease outcome, with no evident decline in effectiveness in the months following the second dose. Six additional sensitivity analyses were conducted to investigate whether these real-world effectiveness estimates could have been biased by an unknown factor (Supplementary Section 4). All analyses generated consistent results indicating similar values for effectiveness measures, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint and the same pattern of declining effectiveness in the months following the second dose (Supplementary Tables 5-10) , as observed in the main analysis (Table 2) . To further validate the study results, effectiveness was estimated using a different method from that of a matched test-negative, case-control study design. Estimates were derived using multivariable logistic regression analysis of associations with a PCR-positive test during the study, and adjusting for prior infection, sex, age, nationality, reason for PCR testing, and calendar week of PCR test (Supplementary Table 11 ). This analysis also generated consistent results, indicating similar values for effectiveness measures, and the same pattern of declining effectiveness in the months following the second dose, as in the main analysis (Table 2 ). BNT162b2-induced protection against infection builds rapidly after the first dose, peaks in the first five weeks after the second dose, but then gradually wanes in subsequent months. The waning appears to accelerate ≥15 weeks after the second dose, with protection being reduced to a negligible level by the 20 th week. While the protection diminished faster against asymptomatic infection than against symptomatic infection, no evidence was found for any appreciable waning of protection against hospitalization and death, which remained robust at about 90% for six months following the second dose. Implications of these findings on infection transmission remain to be clarified, but vaccine breakthrough infections were found recently, in this same population, to be less infectious than primary infections in unvaccinated individuals. 31 Since the immunization campaign prioritized vaccination of persons with severe or multiple chronic conditions and by age group, this pattern of waning of protection could theoretically be cofounded by effects of age and comorbidities. However, this possibility was not supported by our results, as the same pattern of waning of protection was observed for all ages. Notably, old All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint age may serve as a proxy for co-morbid conditions and the number of persons with severe or multiple chronic conditions is small among the young, working age population of Qatar. 11, 12 Infection incidence was driven by different variants over time; thus, it is possible that waning of protection could be confounded by exposure to different variants at different time points. However, this seems unlikely. By far the dominant variant during the study was Beta, 2,4,8-10 and a similar pattern of waning of protection was observed for Alpha, Beta, and Delta. Vaccinated persons presumably have a higher social contact rate than unvaccinated persons, and may also have reduced adherence to safety measures. 32-34 This behavior could reduce real-world effectiveness of the vaccine compared to its biological effectiveness, possibly explaining the waning of protection. However, risk compensation is perhaps more likely to affect the overall level of effectiveness, rather than the waning of protection over time, unless such risk compensation increases with time after the second dose. Emerging evidence supports the findings of this study. An increasing number of studies suggests significant waning of BNT162b2 effectiveness. [35] [36] [37] [38] The findings are also supported by recent reports from Israel and the United States (U.S.) indicating declining BNT162b2 effectiveness against infection with elapsed time and by calendar month. 39-42 Our findings may also explain the observed low effectiveness against Delta in countries where the second dose was implemented three weeks after the first dose, such as in Israel, 39 Qatar, 30 and the U.S., 42 but higher effectiveness against Delta in countries where a delayed schedule has been implemented, such as in Canada 18 and the United Kingdom. 16, 17 This study has limitations. Data on co-morbid conditions were not available; therefore, they could not be explicitly factored into our analysis. However, adjusting for age may have served as a proxy given that co-morbidities are associated with older age. With the young population of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint Qatar, 11, 12 only a small proportion of the study population may have had serious co-morbid conditions. Our findings may not be generalizable to other countries where the elderly constitute a sizable proportion of the total population. Effectiveness was assessed using an observational, test-negative, case-control study design, 14, 15 rather than a randomized, clinical trial design, in which cohorts of vaccinated and unvaccinated individuals were followed up. We have been unable to use a cohort study design due to depletion of the unvaccinated cohorts with the high vaccine coverage. However, the cohort study design applied earlier to the same population of Qatar, yielded similar findings to the test-negative casecontrol design, 2,4 supporting the validity of this standard approach in assessing vaccine effectiveness for respiratory tract infections. 2, 4, [14] [15] [16] [17] [18] The results of this study are also consistent with our earlier effectiveness estimates immediately after the first and second doses, 2,29 noting that the earlier estimates were against (mostly) symptomatic infections with low PCR cycle threshold values, while the present study estimates are against (mostly) asymptomatic infections of both high and low PCR cycle threshold values. Nonetheless, one cannot theoretically exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing with introduction of other testing modalities, such as rapid antigen testing. However, the same findings were reached regardless of the reason for PCR testing, and regardless of whether it was following appearance of symptoms, or because of a mandatory requirement including routine healthcare testing, pre-travel, and at the port of entry. Moreover, with the mass scale of PCR testing in Qatar, where about 5% of the population are tested every week, 5 the likelihood of bias is perhaps minimized. Indeed, the multiple sensitivity All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint and additional analyses conducted to investigate bias, such as by modifying the inclusion and exclusion criteria in various ways, all presented consistent findings. In conclusion, BNT162b2-induced protection against infection appears to peak in the first five weeks after the second dose, but then gradually wanes month by month, before reaching diminished levels by the 20 th week. Meanwhile, BNT162b2-induced protection against hospitalization and death appears to persist with hardly any waning for at least six months following the second dose. These findings suggest that a large proportion of the vaccinated population could lose its protection against infection in the coming months, perhaps increasing the potential for new epidemic waves. These findings argue for a booster vaccination to reinforce immunity against infection, and to avert possible waning in protection against hospitalization and death over time. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Programme for institutional support for the reagents needed for the viral genome sequencing. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article. Statements made herein are solely the responsibility of the authors. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, FMB, and HAK conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 14,15 ‡ Severity, 22 criticality, 22 and fatality 23 were defined as per World Health Organization guidelines. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 14, 15 Variables were included in categorical form as follows: sex (male, female), age (<60 year, ≥60 years), nationality (Bangladeshis, Egyptians, Filipinos, Indians, Nepalese, Pakistani, Qataris, Sri Lankans, Sudanese, and other nationalities), reason for PCR testing (clinical suspicion, contact tracing, healthcare routine testing, survey, port of entry, pre-travel, individual request, and other), calendar week of PCR test starting from January 1, 2021, and prior infection (no prior infection, infection in prior 90 days, infection >90 days ago 43,44 ). ‡ Severity, 22 criticality, 22 and fatality 23 were defined as per World Health Organization guidelines. A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. † An asymptomatic infection was defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection, that is the PCR testing was done as part of a survey, for pre-travel requirement, or at port of entry into the country. ‡ Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. § Vaccine effectiveness was estimated using the test-negative, case-control study design. 14, 15 Supplementary Appendix COVID-19 severity, criticality, and fatality classification .......................... 3 Supplementary Section 2. Laboratory methods ....................................................................................... 4 Supplementary Section 3. Classification of infections by variant type .................................................. 5 Supplementary Section 4. Additional sensitivity analyses ...................................................................... -control studies. ................................................... 9 Supplementary Figure 1. Flowchart describing the population selection process for investigating BNT162b2 vaccine effectiveness. ......................................................................................................... ....................................................................................................................................................... 11 Supplementary Table 3 COVID-19 disease, and fatal COVID-19 disease. ....................................................... 14 COVID-19 disease. .................................................................................................................................... 15 Supplementary Table 6 Table 7 . Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to additionally include as controls persons who had a PCR-negative test during the study, in addition to their PCR positive test during the study. That is, persons with both PCRpositive and PCR-negative tests during the study, January 1, 2021 to August 15, 2021, were included both as cases and as controls, but at different time points. Effectiveness of the BNT162b2 vaccine against any SARS- CoV-2 infection and against any severe, critical, or fatal COVID-19 disease. ....................................................................................................................................................... 17 Supplementary Table 8 . Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all PCR-positive and PCR-negative tests for each person, and regardless of the number of PCR-positive or PCR-negative tests each person had during the study, January 1, and against any severe, critical, or fatal COVID-19 disease. ................................................................ 18 Supplementary Table 9 . Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all PCR-positive and PCR-negative tests for each person, and regardless of the number of PCR-positive or PCR-negative tests each person had during the study, January 1, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with "acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy". 1 Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report. 1 COVID-19 death was defined per WHO classification as "a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19". Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report. 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIAsymphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath™ COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher, USA); tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions. Medicine Laboratory, following standardized protocols. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint Surveillance for SARS-CoV-2 variants in Qatar is based on viral genome sequencing and multiplex, real-time reverse-transcription PCR (RT-qPCR) variant screening 3 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 6, 8 Accordingly, a Delta case was proxied as any "other" case identified through the RT-qPCR based variant screening. All the variant RT-qPCR screening was conducted at the Sidra Medicine Laboratory following standardized protocols. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Additional sensitivity analyses were conducted to investigate whether the generated real-world effectiveness estimates could have been biased by an unknown factor. These analyses included: 1. Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to additionally exclude any case or control with a prior infection, that is any person with a PCR-positive test prior to January 1, 2021, the first day of the study (Supplementary 3. Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to additionally include as controls persons who had a PCR-negative test during the study, in addition to the PCR-positive test during the study (Supplementary Table 7 ). That is, persons with both PCR-positive and PCR-negative tests during the study were included both as cases and as controls, but at different time points; 4. Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all PCR-positive and PCR-negative tests for each person, and regardless of the number of PCR-positive or PCR-negative tests each person had during the study (Supplementary Table 8); 5. Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all PCR-positive and PCR-negative tests for each person, but all PCR-negative All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 27, 2021. ; https://doi.org/10.1101/2021.08.25.21262584 doi: medRxiv preprint tests for persons included as cases were excluded from analysis. That is, no person was included as both a case and a control (Supplementary Table 9 ); 6. Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all persons vaccinated with a vaccine other than BNT162b2, provided that the PCR test was conducted before receiving the first dose of this vaccine and during the study duration (Supplementary Table 10 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 10, 11 ). † Vaccine effectiveness was calculated using the equation: 1 -AOR, that is assuming odds ratio approximates risk ratio for rare outcomes. ‡ A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection. § An asymptomatic infection was defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection. That is, the PCR testing was done as part of a survey, for pre-travel requirement, or at port of entry into the country. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Ministry of Public Health. National Covid-19 Testing and Vaccination Program Data COVID-19) vaccinations. Our World in Data Qatar viral genome sequencing data One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar The test-negative design for estimating influenza vaccine effectiveness Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness Effectiveness of COVID-19 vaccines against variants of concern However, all PCR-negative tests for persons included as cases were References 1. World Health Organization. COVID-19 clinical management: living guidance International guidelines for certification and classification (coding) of COVID-19 as cause of death Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting The test-negative design for estimating influenza vaccine effectiveness Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 12,13 ‡ Severity, 1 criticality, 1 Table 5 . Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to additionally exclude any case or control with a prior infection, that is any person with a PCR-positive test prior to January 1, 2021, the first day of the study. Effectiveness of the BNT162b2 vaccine against any SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19 disease. Effectiveness against hospitalization and death Cases * (PCR-positive) Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, calendar week of PCR test, and status of prior infection. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 12,13 ‡ Severity, 1 criticality, 1 and fatality 2 were defined as per World Health Organization guidelines. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 12,13 ‡ Severity, 1 criticality, 1 and fatality 2 were defined as per World Health Organization guidelines. Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 12,13 ‡ Severity, 1 criticality, 1 and fatality 2 were defined as per World Health Organization guidelines. Supplementary Table 9 . Sensitivity analysis in which study inclusion and exclusion criteria were modified so as to include all PCR-positive and PCR-negative tests for each person, and regardless of the number of PCR-positive or PCR-negative tests each person had during the study, January 1, 2021 to August 15, 2021. However, all PCR-negative tests for persons included as cases were excluded from analysis. That is, no person was included as both a case and a control. Effectiveness of the BNT162b2 vaccine against any SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19 disease. Effectiveness against hospitalization and death Cases * (PCR-positive) Abbreviations: CI, confidence interval; PCR, polymerase chain reaction. * Cases and controls were matched one-to-one by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test. † Vaccine effectiveness was estimated using the test-negative, case-control study design. 12,13 ‡ Severity, 1 criticality, 1 and fatality 2 were defined as per World Health Organization guidelines.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.